uniQure gets bump on latest hemophilia readout

uniQure N.V. (NASDAQ:QURE) added $3.31 (10%) to $36.49 Friday after new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Monday it had

Read the full 378 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE